Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Cancers | Free Full-Text | Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia | HTML
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges | Journal for ImmunoTherapy of Cancer | Full Text
Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development - Clinical Genitourinary Cancer
Mechanism of action of clinically used immunotherapeutic agents. | Download Scientific Diagram
Mechanism of action of the immune checkpoint inhibitors currently under... | Download Scientific Diagram
Merck Pfizer Alliance Strategy in gynecologic oncology
Mechanism of action of nivolumab. | Download Scientific Diagram
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action | Immunotherapy
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. - Abstract - Europe PMC
Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma - Clinical Trials Arena
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
761049Orig1s000
Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study | Journal for ImmunoTherapy of Cancer
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | SpringerLink
Current role of immunotherapy in urologic cancers | The Bulletin
Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder | Urology News
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies - European Journal of Cancer
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
Note for reviewers
Frontiers | Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers | Oncology
Mechanism of Action | BAVENCIO® (avelumab) HCP | Safety Info
An evaluation of avelumab for the treatment of genitourinary tumors
Overview of immune pathways and actions of checkpoint inhibitors. The... | Download Scientific Diagram
Cemiplimab - an overview | ScienceDirect Topics
